Skip to content

Intracoronary administration of Tenecteplase to prevent PCI-related myocardial infarction in patients enriched with attenuated signal coronary plaques

Intracoronary administration of tenecteplase to prevent PCI-related myocardial infarction in patients enriched with attenuated signal coronary plaques

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084840
Enrollment
Unknown
Registered
2024-05-27
Start date
2024-06-01
Completion date
Unknown
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease

Interventions

Experimental group:Immediate intracoronary injection of 4mL of 0.9% NaCl solution containing 4mg of TNK following balloon angioplasty (dilation).
Control group:Immediate intracoronary injection of 4mL of 0.9% NaCl solution following balloon angioplasty (dilation).

Sponsors

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) age =18 years; (2) CAD patients clinically recommended for elective PCI; (3) IVUS confirms lesion length = 20mm and meets the characteristics of EA: plaque showing ultrasound signal attenuation (longitudinal attenuation length =5mm), excluding calcified and dense fibrous plaques; (4) acceptance of terms and conditions of the study and signature of the informed consent form, with a full understanding of the trial content, process, and potential adverse reactions; willing to adhere to medical follow-up.

Exclusion criteria

Exclusion criteria: (1) positive cardiac troponin I (cTnI) prior to percutaneous coronary angiography; (2) coronary artery bypass graft (CABG) lesion; (3) chronic total occlusion (CTO); (4) in-stent restenosis; (5) severe calcification; (6) left main coronary artery disease (LMCAD); (7) intervention of > 1 major coronary artery branch in a single PCI procedure; (8) side branch occlusion or blood flow-affecting dissection during PCI; (9) cardiogenic shock during PCI; (10) vulnerable populations, including individuals with mental disorders, cognitive impairment, critical illness, minors, female participants in pregnancy/lactation or positive pregnancy tests, etc.

Design outcomes

Primary

MeasureTime frame
Incidence of PCI-related MI;

Secondary

MeasureTime frame
Proportion of patients with elevated postoperative high-sensitivity cTnI exceeding 5, 10, 35, and 70 times of the normal baseline.;Incidence of slow-flow after stent implantation and post-dilation;Frame count of angiographic flow after stent implantation and post-dilation.;Incidence of MACE during hospitalization and post-operative 1-month follow up.;

Countries

China

Contacts

Public Contactzhang wenbin

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

3313011@zju.edu.cn+86 137 7757 2567

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026